603858 步长制药
已收盘 09-02 15:00:00
资讯
新帖
简况
步长制药上半年净利降2成：核心产品承压，资本化研发投入、商誉高悬
蓝鲸财经 · 08-31 16:47
步长制药上半年净利降2成：核心产品承压，资本化研发投入、商誉高悬
股市必读：步长制药中报 - 第二季度单季净利润同比下降43.15%
证券之星 · 08-31 09:19
股市必读：步长制药中报 - 第二季度单季净利润同比下降43.15%
步长制药（603858）2026年中报简析：净利润同比下降19.93%
证券之星 · 08-29
步长制药（603858）2026年中报简析：净利润同比下降19.93%
步长制药最新公告：全资子公司获盐酸特比萘芬喷雾剂药品注册证书
证券之星 · 08-28
步长制药最新公告：全资子公司获盐酸特比萘芬喷雾剂药品注册证书
步长制药上半年营收降12%净利降2成 经营现金净额降7成
中金财经 · 08-28
步长制药上半年营收降12%净利降2成 经营现金净额降7成
图解步长制药中报：第二季度单季净利润同比下降43.15%
证券之星 · 08-28
图解步长制药中报：第二季度单季净利润同比下降43.15%
步长制药（603858）披露2026年半年度报告，8月27日股价上涨0.06%
证券之星 · 08-27
步长制药（603858）披露2026年半年度报告，8月27日股价上涨0.06%
步长制药（603858）披露控股子公司签订技术服务（委托）合同补充协议的公告，8月24日股价下跌2.19%
证券之星 · 08-24
步长制药（603858）披露控股子公司签订技术服务（委托）合同补充协议的公告，8月24日股价下跌2.19%
每周股票复盘：步长制药（603858）多个新药临床获受理
证券之星 · 08-23
每周股票复盘：步长制药（603858）多个新药临床获受理
步长制药：注射用艾帕依泊汀α为公司子公司四川泸州步长生物制药有限公司自主研发的治疗用生物制品1类新药
证券之星 · 08-21
步长制药：注射用艾帕依泊汀α为公司子公司四川泸州步长生物制药有限公司自主研发的治疗用生物制品1类新药
股市必读：步长制药新发布《山东步长制药股份有限公司关于控股子公司药品临床试验取得受理通知书的公告》
证券之星 · 08-20
股市必读：步长制药新发布《山东步长制药股份有限公司关于控股子公司药品临床试验取得受理通知书的公告》
步长制药最新公告：控股子公司药品临床试验申请获受理
证券之星 · 08-19
步长制药最新公告：控股子公司药品临床试验申请获受理
股市必读：步长制药新发布《山东步长制药股份有限公司关于控股子公司药品临床试验取得受理通知书的公告》
证券之星 · 08-19
股市必读：步长制药新发布《山东步长制药股份有限公司关于控股子公司药品临床试验取得受理通知书的公告》
每周股票复盘：步长制药（603858）控股子公司拟转让2.00%股权
证券之星 · 08-16
每周股票复盘：步长制药（603858）控股子公司拟转让2.00%股权
股市必读：步长制药新发布《山东步长制药股份有限公司第五届董事会第五十四次会议决议公告》
证券之星 · 08-12
股市必读：步长制药新发布《山东步长制药股份有限公司第五届董事会第五十四次会议决议公告》
步长制药（603858）披露控股子公司拟转让股权公告，8月11日股价下跌0.44%
证券之星 · 08-11
步长制药（603858）披露控股子公司拟转让股权公告，8月11日股价下跌0.44%
每周股票复盘：步长制药（603858）全资子公司完成工商变更
证券之星 · 08-09
每周股票复盘：步长制药（603858）全资子公司完成工商变更
股市必读：XD步长制新发布《山东步长制药股份有限公司关于拟对外投资设立子公司的进展公告》
证券之星 · 08-07
股市必读：XD步长制新发布《山东步长制药股份有限公司关于拟对外投资设立子公司的进展公告》
步长制药（603858）披露拟对外投资设立子公司进展公告，8月5日股价下跌0.89%
证券之星 · 08-05
步长制药（603858）披露拟对外投资设立子公司进展公告，8月5日股价下跌0.89%
股市必读：步长制药新发布《山东步长制药股份有限公司关于全资子公司完成工商变更登记的公告》
证券之星 · 08-05
股市必读：步长制药新发布《山东步长制药股份有限公司关于全资子公司完成工商变更登记的公告》
加载更多
公司概况
公司名称：
山东步长制药股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-18
主营业务：
山东步长制药股份有限公司的主营业务是中成药的研发、生产和销售。公司的主要产品是脑心通胶囊、稳心颗粒、丹红注射液。
发行价格：
55.88
{"stockData":{"symbol":"603858","market":"SH","secType":"STK","nameCN":"步长制药","latestPrice":14.83,"timestamp":1788332401000,"preClose":15.05,"halted":0,"volume":4339075,"delay":0,"changeRate":-0.0146,"floatShares":1055000000,"shares":1055000000,"eps":0.2235,"marketStatus":"已收盘","change":-0.22,"latestTime":"09-02 15:00:00","open":15.03,"high":15.04,"low":14.79,"amount":64402000,"amplitude":0.0166,"askPrice":14.83,"askSize":1,"bidPrice":14.82,"bidSize":261,"shortable":0,"etf":0,"ttmEps":0.2235,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788399000000},"marketStatusCode":5,"adr":0,"adjPreClose":15.05,"symbolType":"stock","openAndCloseTimeList":[[1788312600000,1788319800000],[1788325200000,1788332400000]],"highLimit":16.56,"lowLimit":13.55,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1054568442,"isCdr":false,"pbRate":1.55,"roa":"--","peRate":66.353468,"roe":"4.93%","epsLYR":0.3416,"committee":0.740028,"marketValue":15639000000,"turnoverRate":0.0041,"status":1,"floatMarketCap":15639000000},"requestUrl":"/m/hq/s/603858/","defaultTab":"news","newsList":[{"id":"2663117075","title":"步长制药上半年净利降2成：核心产品承压，资本化研发投入、商誉高悬","url":"https://stock-news.laohu8.com/highlight/detail?id=2663117075","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663117075?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:47","pubTimestamp":1788166078,"startTime":"0","endTime":"0","summary":"核心产品增长乏力、销售回款减少，而巨额资本化研发投入与商誉减值风险仍悬于头顶。核心品种收入下滑，现金流同比骤降68.96%步长制药的业务高度集中于心脑血管中成药领域。步长制药近年来将研发方向从传统中成药延伸至生物药领域。此外，步长制药的商誉问题由来已久。经过持续“排雷”，目前步长制药商誉账面价值已降至约3.24亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788165981914499391","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["603858","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663025515","title":"股市必读：步长制药中报 - 第二季度单季净利润同比下降43.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663025515","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663025515?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:19","pubTimestamp":1788139180,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年第二季度单季度归母净利润1.82亿元，同比下降43.15%。业绩披露要点财务报告2026年中报显示：主营收入50.03亿元，同比下降11.67%；归母净利润5.03亿元，同比下降19.93%；扣非净利润5.09亿元，同比下降17.74%；第二季度单季度主营收入24.24亿元，同比下降15.8%；单季度归母净利润1.82亿元，同比下降43.15%；单季度扣非净利润1.99亿元，同比下降37.7%；负债率50.88%，投资收益-2474.89万元，财务费用5755.58万元，毛利率61.19%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100003471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663165030","title":"步长制药（603858）2026年中报简析：净利润同比下降19.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663165030","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663165030?lang=zh_cn&edition=full","pubTime":"2026-08-29 06:12","pubTimestamp":1787955139,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期步长制药发布2026年中报。根据财报显示，步长制药净利润同比下降19.93%。截至本报告期末，公司营业总收入50.03亿元，同比下降11.67%，归母净利润5.03亿元，同比下降19.93%。按单季度数据看，第二季度营业总收入24.24亿元，同比下降15.8%，第二季度归母净利润1.82亿元，同比下降43.15%。本次财报公布的各项数据指标表现不尽如人意。去年的净利率为1.62%，算上全部成本后，公司产品或服务的附加值不高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900010711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662685800","title":"步长制药最新公告：全资子公司获盐酸特比萘芬喷雾剂药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2662685800","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662685800?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:43","pubTimestamp":1787906588,"startTime":"0","endTime":"0","summary":"步长制药(603858.SH)公告称，公司全资子公司保定天浩制药有限公司近日收到国家药品监督管理局核准签发的盐酸特比萘芬喷雾剂《药品注册证书》。该药品为化学药品4类，非处方药，用于治疗手癣、足癣、体癣等。2023年至2025年，该药品在中国样本医院年度销售额分别为953万元、1,029万元和967万元；中国城市实体药店年度销售额分别为2.73亿元、2.87亿元和3.02亿元。截至2026年7月31日，项目研发费用约244.58万元。本次获证有利于优化产品结构，对经营产生积极影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800038517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","603858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662054687","title":"步长制药上半年营收降12%净利降2成 经营现金净额降7成","url":"https://stock-news.laohu8.com/highlight/detail?id=2662054687","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662054687?lang=zh_cn&edition=full","pubTime":"2026-08-28 14:53","pubTimestamp":1787899986,"startTime":"0","endTime":"0","summary":"中国经济网北京8月28日讯 步长制药昨日披露2026年半年度报告，今年上半年公司实现营业收入50.03亿元，同比下降11.67%；归属于上市公司股东的净利润5.03亿元，同比下降19.93%；归属于上市公司股东的扣非净利润5.09亿元，同比下降17.74%；经营活动产生的现金流量净额2.98亿元，同比下降68.96%。 步长制药本次发行募集资金总额390,042.40万元，扣除发行费用后的募集资金净额为367,143.57万元。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/28/20260828300461.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/28/20260828300461.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260828/32351653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["603858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662769082","title":"图解步长制药中报：第二季度单季净利润同比下降43.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662769082","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662769082?lang=zh_cn&edition=full","pubTime":"2026-08-28 01:52","pubTimestamp":1787853125,"startTime":"0","endTime":"0","summary":"证券之星消息，步长制药2026年中报显示，上半年度公司主营收入50.03亿元，同比下降11.67%；归母净利润5.03亿元，同比下降19.93%；扣非净利润5.09亿元，同比下降17.74%；其中2026年第二季度，公司单季度主营收入24.24亿元，同比下降15.8%；单季度归母净利润1.82亿元，同比下降43.15%；单季度扣非净利润1.99亿元，同比下降37.7%；负债率50.88%，投资收益-2474.89万元，财务费用5755.58万元，毛利率61.19%。财报数据概要请见下图:本文数据来源于步长制药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800005104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085477","title":"步长制药（603858）披露2026年半年度报告，8月27日股价上涨0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085477","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662085477?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:17","pubTimestamp":1787840259,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，步长制药报收于15.51元，较前一交易日上涨0.06%，最新总市值为163.56亿元。该股当日开盘15.58元，最高15.58元，最低15.3元，成交额达6116万元，换手率为0.38%。近日，山东步长制药股份有限公司披露《2026年半年度报告》。公告显示，截至报告期末，公司总资产为19,163,111,357.66元，较上年度末减少0.42%；归属于上市公司股东的净资产为10,058,811,909.24元，较上年度末增长0.47%。经营活动产生的现金流量净额为297,632,870.52元，同比减少68.96%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700055308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","603858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661206862","title":"步长制药（603858）披露控股子公司签订技术服务（委托）合同补充协议的公告，8月24日股价下跌2.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661206862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661206862?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:12","pubTimestamp":1787566329,"startTime":"0","endTime":"0","summary":"截至2026年8月24日收盘，步长制药报收于15.18元，较前一交易日下跌2.19%，最新总市值为160.08亿元。该股当日开盘15.46元，最高15.54元，最低15.1元，成交额达1.2亿元，换手率为0.74%。近日，山东步长制药股份有限公司发布关于控股子公司签订技术服务（委托）合同补充协议的公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400025788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603858","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661144182","title":"每周股票复盘：步长制药（603858）多个新药临床获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2661144182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661144182?lang=zh_cn&edition=full","pubTime":"2026-08-23 04:37","pubTimestamp":1787431029,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，步长制药报收于15.52元，较上周的15.91元下跌2.45%。本周关注点公司公告汇总：BC923注射液临床试验申请获受理，适应症为高血压。山东步长制药股份有限公司控股子公司四川泸州步长生物制药有限公司申报的BC008-1A注射液新增适应症临床试验申请已获国家药品监督管理局受理。山东步长制药股份有限公司对外投资设立的控股子公司山东步长盛世制药有限公司已完成工商登记注册，取得营业执照。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300001131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","603858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661643312","title":"步长制药：注射用艾帕依泊汀α为公司子公司四川泸州步长生物制药有限公司自主研发的治疗用生物制品1类新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2661643312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661643312?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:15","pubTimestamp":1787307315,"startTime":"0","endTime":"0","summary":"投资者提问：2026年07月28日药品通知件送达信息显示注射用艾帕依泊汀α未通过审批，请问公司创新药是自研还是合作模式？注射用艾帕依泊汀α为公司子公司四川泸州步长生物制药有限公司自主研发的治疗用生物制品1类新药。因该药品需进一步完善申报资料，经与国家药品审评中心沟通后，决定撤回注册申请，待完善相关资料后择期重新提交药品上市许可注册申请。截至目前该品种仍处于研发阶段，尚未纳入国家医保药品目录。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100033843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0196","03069","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660420608","title":"股市必读：步长制药新发布《山东步长制药股份有限公司关于控股子公司药品临床试验取得受理通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660420608","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660420608?lang=zh_cn&edition=full","pubTime":"2026-08-20 02:34","pubTimestamp":1787164451,"startTime":"0","endTime":"0","summary":"公司公告汇总山东步长制药股份有限公司关于控股子公司药品临床试验取得受理通知书的公告四川泸州步长生物制药有限公司申报的BC008-1A注射液新增适应症临床试验申请已获国家药品监督管理局受理；该药品为重组抗PD-1/TIGIT人源化双特异性抗体注射液，拟新增适应症为联合贝伐珠单抗用于成人复发CNS WHO 4级脑胶质瘤的治疗；截至2026年7月31日，该项目累计研发投入约11,454.72万元；目前国内外尚无同靶点双功能特异性抗体药物获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000002387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","603858","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660442876","title":"步长制药最新公告：控股子公司药品临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2660442876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660442876?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:24","pubTimestamp":1787135057,"startTime":"0","endTime":"0","summary":"步长制药(603858.SH)公告称，公司控股子公司四川泸州步长生物制药有限公司的“BC008-1A注射液”新增适应症临床试验申请获国家药监局受理。该药品为重组抗PD-1/TIGIT人源化双特异性抗体注射液，拟新增适应症为联合贝伐珠单抗用于成人复发CNSWHO4级脑胶质瘤治疗。截至2026年7月31日，该项目研发投入约1.15亿元。目前国内外尚无同靶点双功能特异性抗体药物获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900032434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660849944","title":"股市必读：步长制药新发布《山东步长制药股份有限公司关于控股子公司药品临床试验取得受理通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660849944","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660849944?lang=zh_cn&edition=full","pubTime":"2026-08-19 01:42","pubTimestamp":1787074930,"startTime":"0","endTime":"0","summary":"公司公告汇总：控股子公司BC923注射液临床试验申请获国家药监局受理，为靶向AGT的化学药品1类，适应症为高血压，累计研发投入约3,175.45万元。公司公告汇总山东步长制药股份有限公司关于控股子公司药品临床试验取得受理通知书的公告山东步长制药股份有限公司控股子公司北京博源润步医药研发有限公司申报的BC923注射液临床试验申请已获国家药品监督管理局受理。目前全球尚无AGT靶点小核酸药物获批上市，同类产品均处于临床或临床前阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","603858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659175728","title":"每周股票复盘：步长制药（603858）控股子公司拟转让2.00%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175728","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175728?lang=zh_cn&edition=full","pubTime":"2026-08-16 02:21","pubTimestamp":1786818069,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，步长制药报收于15.91元，较上周的15.95元下跌0.25%。杭州步长建鑫生物科技有限公司股东李宾拟将其持有的2.00%股权转让给易翠，转让价格为人民币5.5558万元。本次转让后，步长制药持股比例仍为90.00%，不构成关联交易或重大资产重组，不影响公司合并报表范围及财务状况。步长（广州）医学诊断技术有限公司因经营发展需要，法定代表人由薛人珲变更为吴磊。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603858","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658917471","title":"股市必读：步长制药新发布《山东步长制药股份有限公司第五届董事会第五十四次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658917471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658917471?lang=zh_cn&edition=full","pubTime":"2026-08-12 02:22","pubTimestamp":1786472532,"startTime":"0","endTime":"0","summary":"公司公告汇总山东步长制药股份有限公司第五届董事会第五十四次会议决议公告山东步长制药股份有限公司于2026年8月11日召开第五届董事会第五十四次会议，审议通过《关于控股子公司变更法定代表人的议案》和《关于控股子公司股权转让的议案》。两项议案均获全票通过。山东步长制药股份有限公司关于控股子公司拟转让股权的公告杭州步长建鑫生物科技有限公司股东李宾拟将其持有的2.00%股权以5.5558万元价格转让给易翠。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200002170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603858","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658916009","title":"步长制药（603858）披露控股子公司拟转让股权公告，8月11日股价下跌0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658916009","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658916009?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:22","pubTimestamp":1786458144,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，步长制药报收于15.8元，较前一交易日下跌0.44%，最新总市值为166.62亿元。该股当日开盘15.89元，最高16.06元，最低15.75元，成交额达9735.78万元，换手率为0.58%。近日，山东步长制药股份有限公司发布《关于控股子公司拟转让股权的公告》。公告显示，公司控股子公司杭州步长建鑫的股东李宾拟将其持有的2.00%股权以5.5558万元价格转让给易翠。本次转让后，公司持股比例仍为90.00%，不构成关联交易，亦不构成重大资产重组，无需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100038382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658895675","title":"每周股票复盘：步长制药（603858）全资子公司完成工商变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2658895675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658895675?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:20","pubTimestamp":1786213220,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，步长制药报收于15.95元，较上周的15.76元上涨1.21%。本周关注点公司公告汇总：全资子公司杨凌步长制药有限公司完成工商变更登记，经营范围新增中药提取物生产、太阳能发电技术服务等。公司公告汇总山东步长制药股份有限公司全资子公司杨凌步长制药有限公司已完成工商变更登记，取得杨凌示范区市场监督管理局换发的营业执照。四川泸州步长生物制药有限公司完成首期增资扩股并办理工商变更登记，注册资本变更为4.58526316亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","603858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657516306","title":"股市必读：XD步长制新发布《山东步长制药股份有限公司关于拟对外投资设立子公司的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657516306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657516306?lang=zh_cn&edition=full","pubTime":"2026-08-07 02:00","pubTimestamp":1786039246,"startTime":"0","endTime":"0","summary":"公司公告汇总山东步长制药股份有限公司关于拟对外投资设立子公司的进展公告山东步长制药股份有限公司于2026年8月5日与济南福聚长源企业管理中心及自然人邓博睿签署《关于山东步长盛世制药有限公司之合作协议书》，拟共同设立控股子公司山东步长盛世制药有限公司。合资公司注册资本为5,000万元，步长制药认缴3,350万元，持股67%，以货币方式出资。各方约定在2031年6月21日前同比例实缴出资。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700001887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657236555","title":"步长制药（603858）披露拟对外投资设立子公司进展公告，8月5日股价下跌0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657236555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657236555?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:26","pubTimestamp":1785939977,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，步长制药报收于15.66元，较前一交易日下跌0.89%，最新总市值为165.15亿元。该股当日开盘15.8元，最高15.88元，最低15.58元，成交额达8868.46万元，换手率为0.54%。近日，山东步长制药股份有限公司发布《关于拟对外投资设立子公司的进展公告》。合资公司注册资本为5,000万元，步长制药认缴3,350万元，持股67%，以货币方式出资。各方约定在2031年6月21日前同比例实缴出资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","603858"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635195","title":"股市必读：步长制药新发布《山东步长制药股份有限公司关于全资子公司完成工商变更登记的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657635195?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:46","pubTimestamp":1785865575,"startTime":"0","endTime":"0","summary":"公司公告汇总山东步长制药股份有限公司关于全资子公司完成工商变更登记的公告杨凌步长制药有限公司已完成工商变更登记，取得杨凌示范区市场监督管理局换发的营业执照。山东步长制药股份有限公司关于控股子公司增资扩股引进外部投资者、发行可转债及公司放弃优先认购权暨关联交易且公司为控股子公司提供担保的进展公告四川泸州步长生物制药有限公司完成首期增资工商变更登记，注册资本变更为4.58526316亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","603858"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788352111720,"stockEarnings":[{"period":"1week","weight":-0.017},{"period":"1month","weight":-0.034},{"period":"3month","weight":0.0036},{"period":"6month","weight":-0.0648},{"period":"1year","weight":-0.2186},{"period":"ytd","weight":-0.0266}],"compareEarnings":[{"period":"1week","weight":0.0233},{"period":"1month","weight":0.0385},{"period":"3month","weight":-0.0255},{"period":"6month","weight":-0.0313},{"period":"1year","weight":0.0269},{"period":"ytd","weight":0.0028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东步长制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"49384人(较上一季度减少3.49%)","perCapita":"21354股","listingDate":"2016-11-18","address":"山东省菏泽市牡丹区中华西路369号","registeredCapital":"105456万元","survey":" 山东步长制药股份有限公司的主营业务是中成药的研发、生产和销售。公司的主要产品是脑心通胶囊、稳心颗粒、丹红注射液。","listedPrice":55.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"步长制药(603858)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供步长制药(603858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"步长制药,603858,步长制药股票,步长制药股票老虎,步长制药股票老虎国际,步长制药行情,步长制药股票行情,步长制药股价,步长制药股市,步长制药股票价格,步长制药股票交易,步长制药股票购买,步长制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"步长制药(603858)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供步长制药(603858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}